Skip to main content

Table 3 Univariable and multivariable analyses of OS

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

 

Univariable analysis

Multivariable analysis

Variable

 

N

HR (95% CI)

p value

HR (95% CI)

p value

Age, years

< 65

125

1

0.734

–

–

≥65

26

1.09 (0.67–1.77)

 

–

–

Sex

Male

137

1

0.678

–

–

Female

14

0.86 (0.42–1.77)

 

–

–

ECOG PS

0

52

1

0.326

–

–

1–2

99

1.23 (0.82–1.84)

 

–

–

Etiology

HBV

134

1

0.784

–

–

Non-HBV

17

1.09 (0.60–1.98)

 

–

–

Child-Pugh class

A

140

1

0.118

–

–

B

11

1.73 (0.87–3.43)

 

–

–

BCLC stage

B

5

1

0.383

–

–

C

146

1.67 (0.53–5.26)

 

–

–

MVI

No

88

1

< 0.0001

1

0.125

Yes

63

2.17 (1.48–3.18)

 

1.37 (0.92–2.06)

 

EHS

No

15

1

0.775

–

–

Yes

136

1.10 (0.57–2.11)

 

–

–

AFP (ng/mL)

< 200

73

1

< 0.0001

1

0.005

≥200

77

2.27 (1.53–3.37)

 

1.80 (1.19–2.73)

 

cfDNA (ng/μL)

≤0.71a)

76

1

< 0.0001

1

< 0.0001

> 0.71a)

75

3.50 (2.36–5.20)

 

2.51 (1.62–3.89)

 

I-score

≤1637a)

76

1

< 0.0001

1

0.010

>1637a)

75

3.35 (2.24–5.01)

 

1.85 (1.16–2.96)

 
  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, MVI macroscopic vascular invasion, EHS extrahepatic spread, AFP alpha fetoprotein, cfDNA cell-free DNA
  2. a)Median value